Advertisement
Dr. Stogniew will be responsible for Prestwick's pre-clinicaldevelopment, regulatory and patent activities around its portfolio ofproducts including its lead product candidate, tetrabenazine, a highlyselective and reversible dopamine depletor in Phase 3 clinical trialsfor potential use as a treatment for chorea associated with Huntington'sDisease.
Advertisement
He joins Prestwick most recently from Zelos Therapeutics, where he wasExecutive Vice President of Development responsible for pre-clinical,regulatory and patent development.
"With 25 years focused on developing drugs and 25 patents to his name,Marty will immediately help Prestwick as we work to execute and enhanceour pipeline," said George F. Horner III, President and Chief ExecutiveOfficer of Prestwick. "He has made a significant impact in thedevelopment of successful drugs such as Anidulafugin, Amifostine andIdarubicin -- all of which are now on the market and positively impactingpatients' lives."
Dr. Stogniew worked with Mr. Horner at Vicuron Pharmaceuticals, Inc. asExecutive Vice President of Scientific Affairs from 2001 to 2005 beforeVicuron was purchased by Pfizer in 2005 for $1.9 billion. Prior toVicuron, Dr. Stogniew served as Chief Scientific Officer at NextPharmaceuticals, Inc. and as Vice President of Pharmaceutical Sciencesat MedImmune. Dr. Stogniew holds a Ph.D. in Medicinal Chemistry and aB.S. in Pharmacy from the University of Maryland.
About Prestwick
Prestwick is currently managing a portfolio of pipeline productcandidates being studied for CNS conditions with significant unmetneeds, including Huntington's disease, Parkinson's disease, restlesslegs syndrome, schizophrenia, autism, Alzheimer's disease and sleepapnea.
Please go to http://www.prestwickpharma.com for more information.
SOURCE Prestwick Pharmaceuticals, Inc.
